These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28489881)

  • 1. Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition.
    Yamazaki H; Lai YC; Tateno M; Setoguchi A; Goto-Koshino Y; Endo Y; Nakaichi M; Tsujimoto H; Miura N
    PLoS One; 2017; 12(5):e0177305. PubMed ID: 28489881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
    Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
    Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
    Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
    Lohse I; Rasowski J; Cao P; Pintilie M; Do T; Tsao MS; Hill RP; Hedley DW
    Oncotarget; 2016 Jun; 7(23):33571-80. PubMed ID: 27248663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
    Saggar JK; Tannock IF
    Clin Cancer Res; 2015 May; 21(9):2107-14. PubMed ID: 25677696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
    PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
    Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
    Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
    Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
    Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
    Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
    Duyndam MC; van Berkel MP; Dorsman JC; Rockx DA; Pinedo HM; Boven E
    Biochem Pharmacol; 2007 Jul; 74(2):191-201. PubMed ID: 17498666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of hypoxia-inducible factor-1 alpha reduces proliferation, induces apoptosis and attenuates the aggressive phenotype of retinoblastoma WERI-Rb-1 cells under hypoxic conditions.
    Xia T; Cheng H; Zhu Y
    Ann Clin Lab Sci; 2014; 44(2):134-44. PubMed ID: 24795051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Apoptotic Effect of HIF-1α Inhibition Combined with Glucose plus Insulin Treatment on Gastric Cancer under Hypoxic Conditions.
    Tanaka T; Kitajima Y; Miyake S; Yanagihara K; Hara H; Nishijima-Matsunobu A; Baba K; Shida M; Wakiyama K; Nakamura J; Noshiro H
    PLoS One; 2015; 10(9):e0137257. PubMed ID: 26339797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
    Hu J; Handisides DR; Van Valckenborgh E; De Raeve H; Menu E; Vande Broek I; Liu Q; Sun JD; Van Camp B; Hart CP; Vanderkerken K
    Blood; 2010 Sep; 116(9):1524-7. PubMed ID: 20530289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia inducible factor 1α expression and effects of its inhibitors in canine lymphoma.
    Kambayashi S; Igase M; Kobayashi K; Kimura A; Shimokawa Miyama T; Baba K; Noguchi S; Mizuno T; Okuda M
    J Vet Med Sci; 2015 Nov; 77(11):1405-12. PubMed ID: 26050843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-targeting therapy for intestinal T-cell lymphoma in dogs: Preclinical study using 3D in vitro models.
    Yamazaki H; Tanaka T; Nishida H; Hatoya S; Akiyoshi H
    Vet Comp Oncol; 2023 Mar; 21(1):12-19. PubMed ID: 36054173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
    Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
    PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.